Skip to main content
Premium Trial:

Request an Annual Quote

China's SFDA Approves China Med Tech's Companion Dx for Colorectal Cancer

NEW YORK (GenomeWeb News) – China Medical Technologies today announced that its PCR-based KRAS assay has been approved in China as a companion diagnostic for an undisclosed drug targeting colorectal cancer.

The assay was approved by China's State Food and Drug Administration for the detection of specific mutations in the KRAS gene. According to China Med Tech, about 40 percent of colorectal cancer patients have mutations to the gene that may render them non-responsive to the targeted drug.

About 170,000 new colorectal cancer cases are diagnosed each year in China, with the incidence rate expected to increase.

The PCR KRAS assay is the most recent addition to China Med Tech's portfolio of SFDA-approved companion diagnostics, which includes its FISH HER-2 kit for breast cancer and stomach cancer drugs, the FISH BCR/ABL kit for a drug targeting leukemia, and the FISH EGFR kit and PCR EGFR assay for a drug targeting non-small cell lung cancer.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.